According to an announcement made by Bayer HealthCare Pharmaceuticals, the Phase III trial of its investigational compound regorafenib (BAY 73-4506) to treat individuals with metastatic colorectal cancer (mCRC) whose disease progressed after approved standard treatments has reached its initial endpoint of statistically significant improvement in overall survival. The result was obtained from a pre-planned interim examination carried out by an independent Data Monitoring Committee (DMC) of the CORRECT (Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. Following the suggestion of the DMA, the investigation has been unblinded and participants in the placebo group will be offered treatment with regorafenib. The study revealed that the safety and tolerability of the drug were mostly as anticipated.
New study highlights importance of adenoma detection rate as quality indicator for colonoscopy Physicians who listen to Mozart while performing colonoscopy may increase their detection rates of precancerous polyps, according to the results of a new study unveiled at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC. The study, "The 'Mozart Effect' and Adenoma Detection, " by Catherine Noelle O'Shea, DO and David Wolf, MD, of the University of Texas Health Science Center at Houston, found adenoma detection rate - the proportion of patients undergoing screening colonoscopy in whom an adenomatous polyp is found and an important measure of a high quality endoscopic exam -- increased from baseline values with music compared to without for two endoscopists whose baseline adenoma detection rates were calculated over a one-year period prior to the start of the study.
After demonstrating that light accurately detected pre-cancerous cells in the lining of the esophagus, Duke University bioengineers turned their technology to the colon and have achieved similar results in a series of preliminary experiments. This technology could be a non-invasive way for physicians to detect abnormal cells, or dysplasia, which have the potential of turning cancerous. These cells are in the epithelium, or lining, of various tissues, including the esophagus and colon. Current biopsy techniques require physicians to take many random tissue samples, and for some disorders of the colon, these procedures can be disfiguring and life-changing. Instead of taking tissue samples, the new system would aim short bursts of light from the tip of an endoscope at locations suspected of having disease.
Assesses impact of pre-cancerous changes in the far reaches of the colon The first study to assess improvements in detection of pre-cancerous growths in the colon through intensive physician training was presented at the American College of Gastroenterology's 76th Annual Scientific Meeting, where colorectal cancer detection was an important focus of the scientific presentations. Other studies highlighted the relationship between the location of pre-cancerous growths in the colon and the development of colorectal cancer in high risk populations, as well as detection rates for pre-cancerous growths in the upper reaches of the colon. Highlights of Colorectal Cancer Research from the ACG Annual Scientific Meeting Investigators from the Mayo Clinic in Jacksonville, FL reported results of a prospective study of the impact of training for physicians who perform colorectal cancer screening which revealed that detection of pre-cancerous growths can be improved significantly with structured endoscopist training, according to research conducted by Susan T.
Researchers may have found a specific dietary pattern linked to levels of C-peptide concentrations that increase a woman's risk for colorectal cancer. "High red meat intake, fish intake, sugar-sweetened beverage intake, but low coffee, whole grains and high-fat dairy intake, when taken as a whole, seemed to be associated with higher levels of C-peptide in the blood, " said Teresa T. Fung, S.D., R.D., professor of nutrition at Simmons College in Boston, who presented the data at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011. C-peptide is a marker of insulin secretion that can be measured in a person's blood. High levels of insulin may promote cell growth and multiplication. One of the major characteristics of cancer is aberrant cell growth.